primary sources . please improve this by adding secondary or tertiary sources . june 2009 learn how and when to remove this template message nicox s.a. type soci t anonyme traded as euronext cox industry pharmaceuticals founded 1996 1996 headquarters sophia antipolis france key people michele garufi chairman of the board products naproxcinod revenue 3 36 million 2009 net income 73 887 million 2008 total equity 102 069 million 2009 number of employees 133 2009 subsidiaries nicox research institute srl nicox inc. website www.nicox.com nicox s.a. is a french pharmaceutical company . its headquarters are at sophia antipolis u.s. headquarters in warren new jersey opened in october 2007 . louis ignarro co recipient of the 1998 nobel prize in physiology or medicine for demonstrating the signalling properties of nitric oxide is a member of the scientific committee of the company and bengt samuelsson nobel laureate 1982 serves as director on the company board . the company focuses on the uses of the medical properties of nitric oxide . it has several molecules in the pipeline and its lead compound was an anti inflammatory drug naproxcinod of the cinod cox inhibiting nitric oxide donator class for the treatment of osteoarthritis . this class of drugs was first described by dr. john l. wallace 1 and colleagues . 2 the company has ongoing development partnerships with bausch & lomb and merck . 3 nicox was financed with venture capital provided by a syndicate including apax france sofinnova auriga and healthcap . the company went public on the paris stock exchange in 1999 . the market capitalisation of the company was 1 billion as of january 2008 . it is listed on euronext the french stock exchange and is part of the cac mid 100 stock market index . it has been included in the sbf 120 index since 18 june 2007 . oppenheimer funds is its first shareholder with 25 % of its capital . in july 2014 nicox announced its intention to acquire aciex therapeutics for up to 120 million . 4 naproxcinod edit this section needs additional citations for verification . please help improve this article by adding citations to reliable sources . unsourced material may be challenged and removed . april 2011 learn how and when to remove this template message naproxcinod was the company s lead compound until 2011 . the company finished three phase iii clinical trials . the first of these studies to be published showed that naproxcinod had similar efficacy to naproxen measured in womac pain function and patient global assessment in controlling signs and symptoms of osteoarthritis . 5 it has been well documented that non steroidal anti inflammatory drugs increase blood pressure and naproxen is one of the safest in this regard . 6 meanwhile naproxcinod had similar effects on blood pressure to placebo which is considered neutral while the comparator naproxen sold under the brand aleve in the united states showed a statistically significant increase in blood pressure . this difference was especially marked for those patients taking ras blockers ace inhibitors arbs and beta blockers . this means that naproxcinod could have become an option for patients with osteoarthritis who needed to take nsaids . in september 2009 nicox filed for regulatory approval of naproxcinod with the united states food and drug administration fda and the european medicines agency . on 12 may 2010 an fda advisory committee voted against approval questioning the safety of the drug . nicox has appealed this decision . 3 subsequently in april 2011 the company withdrew its european application after it became clear that an eu expert panel was going to fail to render a positive review of nicox s clinical data . 3 references edit john l. wallace homepage at farncombe institute mcmaster university wallace jl reuter b cicala c mcknight w grisham mb cirino g july 1994 . novel nonsteroidal anti inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat . gastroenterology . 107 1 173 179 . pmid 8020659 . a b c nicox pulls drug application shares plunge . reuters . 20 april 2011 . retrieved 21 april 2011 . http www.genengnews.com gen news highlights nicox buys aciex for up to 120m 81250058 william b. white ; thomas j. schnitzer ; rosana fleming ; brigitte duquesroix ; maarten beekman 5 may 2009 effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis american journal of cardiology elsevier published 15 september 2009 104 6 pp. 840 845 doi 10.1016 j.amjcard .2009.05.014 issn 1879 1913 oclc 39263367 pmid 19733721 retrieved 21 april 2011 frishman william h. 21 march 2002 effects of nonsteroidal anti inflammatory drug therapy on blood pressure and peripheral edema american journal of cardiology elsevier 89 6 pp. 18 25 doi 10.1016 s0002 9149 02 02233 6 issn 1879 1913 oclc 39263367 retrieved 21 april 2011 external links edit official website of nicox nitric oxide knowledge center website of nicox retrieved from https en.wikipedia.org w index.php title nicox & oldid 723671480 categories pharmaceutical companies of francesbf 120hidden categories articles lacking reliable references from june 2009all articles lacking reliable referencesarticles needing additional references from april 2011all articles needing additional references navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages deutschfran ais edit links this page was last modified on 4 june 2016 at 13 17 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view